Cipla Ltd (Cipla) focuses on the research, development, production, and commercialization of generic and branded therapies, and active pharmaceutical ingredients (APIs). The company's portfolio includes respiratory, oncology, HIV/AIDS, diagnostics, and over-the-counter (OTC) products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cipla is dedicated to nurturing and enhancing its research capabilities to drive meaningful advancements in healthcare. The company's Integrated Product Development (IPD) team, comprising over 1,700 experts, is responsible for its R&D efforts across five cutting-edge facilities in New York, Maharashtra, and Karnataka. Cipla is actively working on oligonucleotide therapies, respiratory therapies with low Global Warming Potential (GWP) propellants, and biosimilars. The company is also focused on expanding its global reach and ensuring healthcare accessibility and affordability. The company is focused on advancing its capabilities in respiratory healthcare through enhanced particle engineering and in-vitro characterization for inhalation products. The upgraded device laboratories focus on new developments in Metered Dose Inhalers (MDIs). Cipla’s joint venture with Kemwell Biopharma (Aspergen Inc) has made notable progress in biosimilar development. The company’s new R&D facility in India is dedicated to cutting-edge in-vitro functional potency studies for high-value products like Peptides, Biosimilars, and Oligonucleotides. In the field of oligonucleotides, Cipla has advanced its first Abbreviated New Drug Application (ANDA) and enhanced its analytical capabilities at facilities in India and the US. The company also conducted clinical research including 31 trials initiated across various phases, involving over 1,000 patients nationwide. It also received approvals for Plazomicin Injection and Pirfenidone Gel in India and conducted multiple pre-clinical studies and innovative drug research. In FY2025, Cipla launched 133 new products and filed 2,472 Drug Master Files (DMFs). As of March 2025, Cipla's ANDA and New Drug Application (NDA) portfolio included 284 ANDAs and NDA's, and 158 Cumulative US DMFs. As of March 2025, the company has been granted 279 patents. The company spent INR3,761.6 million on its R&D activities during FY2025, which as a percentage of revenue stood at 1.4%.